Loading…

Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor

The intricate involvement of the serotonin 5-HT 2A receptor (5-HT 2A R) both in schizophrenia and in the activity of antipsychotic drugs is widely acknowledged. The currently marketed antipsychotic drugs, although effective in managing the symptoms of schizophrenia to a certain extent, are not witho...

Full description

Saved in:
Bibliographic Details
Published in:Molecular psychiatry 2024-09, Vol.29 (9), p.2753-2764
Main Authors: Gaitonde, Supriya A., Avet, Charlotte, de la Fuente Revenga, Mario, Blondel-Tepaz, Elodie, Shahraki, Aida, Pastor, Adrian Morales, Talagayev, Valerij, Robledo, Patricia, Kolb, Peter, Selent, Jana, González-Maeso, Javier, Bouvier, Michel
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c403t-d198b8775944ccdca59d04d8ade8cdf1fb38eab3ebbe956ae82ca10607eda39b3
container_end_page 2764
container_issue 9
container_start_page 2753
container_title Molecular psychiatry
container_volume 29
creator Gaitonde, Supriya A.
Avet, Charlotte
de la Fuente Revenga, Mario
Blondel-Tepaz, Elodie
Shahraki, Aida
Pastor, Adrian Morales
Talagayev, Valerij
Robledo, Patricia
Kolb, Peter
Selent, Jana
González-Maeso, Javier
Bouvier, Michel
description The intricate involvement of the serotonin 5-HT 2A receptor (5-HT 2A R) both in schizophrenia and in the activity of antipsychotic drugs is widely acknowledged. The currently marketed antipsychotic drugs, although effective in managing the symptoms of schizophrenia to a certain extent, are not without their repertoire of serious side effects. There is a need for better therapeutics to treat schizophrenia for which understanding the mechanism of action of the current antipsychotic drugs is imperative. With bioluminescence resonance energy transfer (BRET) assays, we trace the signaling signature of six antipsychotic drugs belonging to three generations at the 5-HT 2A R for the entire spectrum of signaling pathways activated by serotonin (5-HT). The antipsychotic drugs display previously unidentified pathway preference at the level of the individual Gα subunits and β-arrestins. In particular, risperidone, clozapine, olanzapine and haloperidol showed G protein-selective inverse agonist activity. In addition, G protein-selective partial agonism was found for aripiprazole and cariprazine. Pathway-specific apparent dissociation constants determined from functional analyses revealed distinct coupling-modulating capacities of the tested antipsychotics at the different 5-HT-activated pathways. Computational analyses of the pharmacological and structural fingerprints support a mechanistically based clustering that recapitulate the clinical classification (typical/first generation, atypical/second generation, third generation) of the antipsychotic drugs. The study provides a new framework to functionally classify antipsychotics that should represent a useful tool for the identification of better and safer neuropsychiatric drugs and allows formulating hypotheses on the links between specific signaling cascades and in the clinical outcomes of the existing drugs.
doi_str_mv 10.1038/s41380-024-02531-7
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11420065</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3031132256</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-d198b8775944ccdca59d04d8ade8cdf1fb38eab3ebbe956ae82ca10607eda39b3</originalsourceid><addsrcrecordid>eNp9UcFqGzEQFSWldt3-QE6CXHLZRlpJu9pTCCFpCoYUkp6FVpq1ZdaSK2kD-fvIsWloDjkMMzDvPd7MQ-iUkh-UMHmROGWSVKTmpQSjVfsJzSlvm0qIVp6UmYmu4lTyGfqa0oaQ_VJ8QTMmRUN5087Rw--1jlttwhhWzugRD86vIO6i8xmHAWuf3S49m3XIzmAbp1XCOuO8Bpwghhy881hUd4_1FY5gYJdD_IY-D3pM8P3YF-jP7c3j9V21vP_56_pqWRlOWK4s7WQv21Z0nBtjjRadJdxKbUEaO9ChZxJ0z6DvoRONBlkbTUlDWrCadT1boMuD7m7qt2AN-Bz1qIr3rY7PKmin_t94t1ar8KQo5TUhjSgK50eFGP5OkLLaumRgHLWHMCXFCKOU1bVoCvTsHXQTpujLfYpRIjnngsmCqg8oE0NKEYZ_bihR-9DUITRVQlOvoam2kNiBlPZvL99_k_6A9QKVoppx</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3108444538</pqid></control><display><type>article</type><title>Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor</title><source>Springer Nature</source><source>Alma/SFX Local Collection</source><creator>Gaitonde, Supriya A. ; Avet, Charlotte ; de la Fuente Revenga, Mario ; Blondel-Tepaz, Elodie ; Shahraki, Aida ; Pastor, Adrian Morales ; Talagayev, Valerij ; Robledo, Patricia ; Kolb, Peter ; Selent, Jana ; González-Maeso, Javier ; Bouvier, Michel</creator><creatorcontrib>Gaitonde, Supriya A. ; Avet, Charlotte ; de la Fuente Revenga, Mario ; Blondel-Tepaz, Elodie ; Shahraki, Aida ; Pastor, Adrian Morales ; Talagayev, Valerij ; Robledo, Patricia ; Kolb, Peter ; Selent, Jana ; González-Maeso, Javier ; Bouvier, Michel</creatorcontrib><description>The intricate involvement of the serotonin 5-HT 2A receptor (5-HT 2A R) both in schizophrenia and in the activity of antipsychotic drugs is widely acknowledged. The currently marketed antipsychotic drugs, although effective in managing the symptoms of schizophrenia to a certain extent, are not without their repertoire of serious side effects. There is a need for better therapeutics to treat schizophrenia for which understanding the mechanism of action of the current antipsychotic drugs is imperative. With bioluminescence resonance energy transfer (BRET) assays, we trace the signaling signature of six antipsychotic drugs belonging to three generations at the 5-HT 2A R for the entire spectrum of signaling pathways activated by serotonin (5-HT). The antipsychotic drugs display previously unidentified pathway preference at the level of the individual Gα subunits and β-arrestins. In particular, risperidone, clozapine, olanzapine and haloperidol showed G protein-selective inverse agonist activity. In addition, G protein-selective partial agonism was found for aripiprazole and cariprazine. Pathway-specific apparent dissociation constants determined from functional analyses revealed distinct coupling-modulating capacities of the tested antipsychotics at the different 5-HT-activated pathways. Computational analyses of the pharmacological and structural fingerprints support a mechanistically based clustering that recapitulate the clinical classification (typical/first generation, atypical/second generation, third generation) of the antipsychotic drugs. The study provides a new framework to functionally classify antipsychotics that should represent a useful tool for the identification of better and safer neuropsychiatric drugs and allows formulating hypotheses on the links between specific signaling cascades and in the clinical outcomes of the existing drugs.</description><identifier>ISSN: 1359-4184</identifier><identifier>ISSN: 1476-5578</identifier><identifier>EISSN: 1476-5578</identifier><identifier>DOI: 10.1038/s41380-024-02531-7</identifier><identifier>PMID: 38561467</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/109 ; 13/95 ; 14/33 ; 14/35 ; 14/5 ; 631/154 ; 631/1647 ; 692/699/476/1799 ; 82/80 ; 96/10 ; 96/106 ; Antipsychotics ; Aripiprazole ; Arrestin ; Behavioral Sciences ; Biological Psychology ; Bioluminescence ; Clozapine ; Drugs ; Haloperidol ; Inverse agonists ; Medicine ; Medicine &amp; Public Health ; Mental disorders ; Neurosciences ; Olanzapine ; Pharmacotherapy ; Psychiatry ; Psychotropic drugs ; Risperidone ; Schizophrenia ; Serotonin ; Serotonin S2 receptors ; Signal transduction</subject><ispartof>Molecular psychiatry, 2024-09, Vol.29 (9), p.2753-2764</ispartof><rights>The Author(s) 2024</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c403t-d198b8775944ccdca59d04d8ade8cdf1fb38eab3ebbe956ae82ca10607eda39b3</cites><orcidid>0000-0003-3105-3204 ; 0000-0002-1907-9594 ; 0000-0002-7941-0939 ; 0000-0003-4089-614X ; 0000-0003-1128-0100</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids></links><search><creatorcontrib>Gaitonde, Supriya A.</creatorcontrib><creatorcontrib>Avet, Charlotte</creatorcontrib><creatorcontrib>de la Fuente Revenga, Mario</creatorcontrib><creatorcontrib>Blondel-Tepaz, Elodie</creatorcontrib><creatorcontrib>Shahraki, Aida</creatorcontrib><creatorcontrib>Pastor, Adrian Morales</creatorcontrib><creatorcontrib>Talagayev, Valerij</creatorcontrib><creatorcontrib>Robledo, Patricia</creatorcontrib><creatorcontrib>Kolb, Peter</creatorcontrib><creatorcontrib>Selent, Jana</creatorcontrib><creatorcontrib>González-Maeso, Javier</creatorcontrib><creatorcontrib>Bouvier, Michel</creatorcontrib><title>Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor</title><title>Molecular psychiatry</title><addtitle>Mol Psychiatry</addtitle><description>The intricate involvement of the serotonin 5-HT 2A receptor (5-HT 2A R) both in schizophrenia and in the activity of antipsychotic drugs is widely acknowledged. The currently marketed antipsychotic drugs, although effective in managing the symptoms of schizophrenia to a certain extent, are not without their repertoire of serious side effects. There is a need for better therapeutics to treat schizophrenia for which understanding the mechanism of action of the current antipsychotic drugs is imperative. With bioluminescence resonance energy transfer (BRET) assays, we trace the signaling signature of six antipsychotic drugs belonging to three generations at the 5-HT 2A R for the entire spectrum of signaling pathways activated by serotonin (5-HT). The antipsychotic drugs display previously unidentified pathway preference at the level of the individual Gα subunits and β-arrestins. In particular, risperidone, clozapine, olanzapine and haloperidol showed G protein-selective inverse agonist activity. In addition, G protein-selective partial agonism was found for aripiprazole and cariprazine. Pathway-specific apparent dissociation constants determined from functional analyses revealed distinct coupling-modulating capacities of the tested antipsychotics at the different 5-HT-activated pathways. Computational analyses of the pharmacological and structural fingerprints support a mechanistically based clustering that recapitulate the clinical classification (typical/first generation, atypical/second generation, third generation) of the antipsychotic drugs. The study provides a new framework to functionally classify antipsychotics that should represent a useful tool for the identification of better and safer neuropsychiatric drugs and allows formulating hypotheses on the links between specific signaling cascades and in the clinical outcomes of the existing drugs.</description><subject>13/109</subject><subject>13/95</subject><subject>14/33</subject><subject>14/35</subject><subject>14/5</subject><subject>631/154</subject><subject>631/1647</subject><subject>692/699/476/1799</subject><subject>82/80</subject><subject>96/10</subject><subject>96/106</subject><subject>Antipsychotics</subject><subject>Aripiprazole</subject><subject>Arrestin</subject><subject>Behavioral Sciences</subject><subject>Biological Psychology</subject><subject>Bioluminescence</subject><subject>Clozapine</subject><subject>Drugs</subject><subject>Haloperidol</subject><subject>Inverse agonists</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mental disorders</subject><subject>Neurosciences</subject><subject>Olanzapine</subject><subject>Pharmacotherapy</subject><subject>Psychiatry</subject><subject>Psychotropic drugs</subject><subject>Risperidone</subject><subject>Schizophrenia</subject><subject>Serotonin</subject><subject>Serotonin S2 receptors</subject><subject>Signal transduction</subject><issn>1359-4184</issn><issn>1476-5578</issn><issn>1476-5578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9UcFqGzEQFSWldt3-QE6CXHLZRlpJu9pTCCFpCoYUkp6FVpq1ZdaSK2kD-fvIsWloDjkMMzDvPd7MQ-iUkh-UMHmROGWSVKTmpQSjVfsJzSlvm0qIVp6UmYmu4lTyGfqa0oaQ_VJ8QTMmRUN5087Rw--1jlttwhhWzugRD86vIO6i8xmHAWuf3S49m3XIzmAbp1XCOuO8Bpwghhy881hUd4_1FY5gYJdD_IY-D3pM8P3YF-jP7c3j9V21vP_56_pqWRlOWK4s7WQv21Z0nBtjjRadJdxKbUEaO9ChZxJ0z6DvoRONBlkbTUlDWrCadT1boMuD7m7qt2AN-Bz1qIr3rY7PKmin_t94t1ar8KQo5TUhjSgK50eFGP5OkLLaumRgHLWHMCXFCKOU1bVoCvTsHXQTpujLfYpRIjnngsmCqg8oE0NKEYZ_bihR-9DUITRVQlOvoam2kNiBlPZvL99_k_6A9QKVoppx</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Gaitonde, Supriya A.</creator><creator>Avet, Charlotte</creator><creator>de la Fuente Revenga, Mario</creator><creator>Blondel-Tepaz, Elodie</creator><creator>Shahraki, Aida</creator><creator>Pastor, Adrian Morales</creator><creator>Talagayev, Valerij</creator><creator>Robledo, Patricia</creator><creator>Kolb, Peter</creator><creator>Selent, Jana</creator><creator>González-Maeso, Javier</creator><creator>Bouvier, Michel</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3105-3204</orcidid><orcidid>https://orcid.org/0000-0002-1907-9594</orcidid><orcidid>https://orcid.org/0000-0002-7941-0939</orcidid><orcidid>https://orcid.org/0000-0003-4089-614X</orcidid><orcidid>https://orcid.org/0000-0003-1128-0100</orcidid></search><sort><creationdate>20240901</creationdate><title>Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor</title><author>Gaitonde, Supriya A. ; Avet, Charlotte ; de la Fuente Revenga, Mario ; Blondel-Tepaz, Elodie ; Shahraki, Aida ; Pastor, Adrian Morales ; Talagayev, Valerij ; Robledo, Patricia ; Kolb, Peter ; Selent, Jana ; González-Maeso, Javier ; Bouvier, Michel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-d198b8775944ccdca59d04d8ade8cdf1fb38eab3ebbe956ae82ca10607eda39b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>13/109</topic><topic>13/95</topic><topic>14/33</topic><topic>14/35</topic><topic>14/5</topic><topic>631/154</topic><topic>631/1647</topic><topic>692/699/476/1799</topic><topic>82/80</topic><topic>96/10</topic><topic>96/106</topic><topic>Antipsychotics</topic><topic>Aripiprazole</topic><topic>Arrestin</topic><topic>Behavioral Sciences</topic><topic>Biological Psychology</topic><topic>Bioluminescence</topic><topic>Clozapine</topic><topic>Drugs</topic><topic>Haloperidol</topic><topic>Inverse agonists</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mental disorders</topic><topic>Neurosciences</topic><topic>Olanzapine</topic><topic>Pharmacotherapy</topic><topic>Psychiatry</topic><topic>Psychotropic drugs</topic><topic>Risperidone</topic><topic>Schizophrenia</topic><topic>Serotonin</topic><topic>Serotonin S2 receptors</topic><topic>Signal transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gaitonde, Supriya A.</creatorcontrib><creatorcontrib>Avet, Charlotte</creatorcontrib><creatorcontrib>de la Fuente Revenga, Mario</creatorcontrib><creatorcontrib>Blondel-Tepaz, Elodie</creatorcontrib><creatorcontrib>Shahraki, Aida</creatorcontrib><creatorcontrib>Pastor, Adrian Morales</creatorcontrib><creatorcontrib>Talagayev, Valerij</creatorcontrib><creatorcontrib>Robledo, Patricia</creatorcontrib><creatorcontrib>Kolb, Peter</creatorcontrib><creatorcontrib>Selent, Jana</creatorcontrib><creatorcontrib>González-Maeso, Javier</creatorcontrib><creatorcontrib>Bouvier, Michel</creatorcontrib><collection>SpringerOpen</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gaitonde, Supriya A.</au><au>Avet, Charlotte</au><au>de la Fuente Revenga, Mario</au><au>Blondel-Tepaz, Elodie</au><au>Shahraki, Aida</au><au>Pastor, Adrian Morales</au><au>Talagayev, Valerij</au><au>Robledo, Patricia</au><au>Kolb, Peter</au><au>Selent, Jana</au><au>González-Maeso, Javier</au><au>Bouvier, Michel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor</atitle><jtitle>Molecular psychiatry</jtitle><stitle>Mol Psychiatry</stitle><date>2024-09-01</date><risdate>2024</risdate><volume>29</volume><issue>9</issue><spage>2753</spage><epage>2764</epage><pages>2753-2764</pages><issn>1359-4184</issn><issn>1476-5578</issn><eissn>1476-5578</eissn><abstract>The intricate involvement of the serotonin 5-HT 2A receptor (5-HT 2A R) both in schizophrenia and in the activity of antipsychotic drugs is widely acknowledged. The currently marketed antipsychotic drugs, although effective in managing the symptoms of schizophrenia to a certain extent, are not without their repertoire of serious side effects. There is a need for better therapeutics to treat schizophrenia for which understanding the mechanism of action of the current antipsychotic drugs is imperative. With bioluminescence resonance energy transfer (BRET) assays, we trace the signaling signature of six antipsychotic drugs belonging to three generations at the 5-HT 2A R for the entire spectrum of signaling pathways activated by serotonin (5-HT). The antipsychotic drugs display previously unidentified pathway preference at the level of the individual Gα subunits and β-arrestins. In particular, risperidone, clozapine, olanzapine and haloperidol showed G protein-selective inverse agonist activity. In addition, G protein-selective partial agonism was found for aripiprazole and cariprazine. Pathway-specific apparent dissociation constants determined from functional analyses revealed distinct coupling-modulating capacities of the tested antipsychotics at the different 5-HT-activated pathways. Computational analyses of the pharmacological and structural fingerprints support a mechanistically based clustering that recapitulate the clinical classification (typical/first generation, atypical/second generation, third generation) of the antipsychotic drugs. The study provides a new framework to functionally classify antipsychotics that should represent a useful tool for the identification of better and safer neuropsychiatric drugs and allows formulating hypotheses on the links between specific signaling cascades and in the clinical outcomes of the existing drugs.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>38561467</pmid><doi>10.1038/s41380-024-02531-7</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-3105-3204</orcidid><orcidid>https://orcid.org/0000-0002-1907-9594</orcidid><orcidid>https://orcid.org/0000-0002-7941-0939</orcidid><orcidid>https://orcid.org/0000-0003-4089-614X</orcidid><orcidid>https://orcid.org/0000-0003-1128-0100</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1359-4184
ispartof Molecular psychiatry, 2024-09, Vol.29 (9), p.2753-2764
issn 1359-4184
1476-5578
1476-5578
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11420065
source Springer Nature; Alma/SFX Local Collection
subjects 13/109
13/95
14/33
14/35
14/5
631/154
631/1647
692/699/476/1799
82/80
96/10
96/106
Antipsychotics
Aripiprazole
Arrestin
Behavioral Sciences
Biological Psychology
Bioluminescence
Clozapine
Drugs
Haloperidol
Inverse agonists
Medicine
Medicine & Public Health
Mental disorders
Neurosciences
Olanzapine
Pharmacotherapy
Psychiatry
Psychotropic drugs
Risperidone
Schizophrenia
Serotonin
Serotonin S2 receptors
Signal transduction
title Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T19%3A29%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacological%20fingerprint%20of%20antipsychotic%20drugs%20at%20the%20serotonin%205-HT2A%20receptor&rft.jtitle=Molecular%20psychiatry&rft.au=Gaitonde,%20Supriya%20A.&rft.date=2024-09-01&rft.volume=29&rft.issue=9&rft.spage=2753&rft.epage=2764&rft.pages=2753-2764&rft.issn=1359-4184&rft.eissn=1476-5578&rft_id=info:doi/10.1038/s41380-024-02531-7&rft_dat=%3Cproquest_pubme%3E3031132256%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c403t-d198b8775944ccdca59d04d8ade8cdf1fb38eab3ebbe956ae82ca10607eda39b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3108444538&rft_id=info:pmid/38561467&rfr_iscdi=true